Economic impact of dengue in Mexico considering reported cases for 2012 to 2016
Por:
Zubieta-Zavala A., López-Cervantes M., Salinas-Escudero G., Ramírez-Chávez A., Castañeda J.R., Hernández-Gaytán S.I., López Yescas J.G., Durán-Arenas L.
Publicada:
1 dic 2018
Resumen:
Background
Given that dengue disease is growing and may progress to dengue
hemorrhagic fever (DHF), data on economic cost and disease burden are
important. However, data for Mexico are limited.
Methodology/Principal findings
Burden of dengue fever (DF) and DHF in Mexico was assessed using
official databases for epidemiological information, disabilities weights
from Shepard et al, the reported number of cases and deaths, and costs.
Overall costs of dengue were summed from direct medical costs to the
health system, cost of dengue to the patient (out-of-pocket expenses
[medical and non-medical], indirect costs [loss of earnings, patient
and/or caregiver]), and other government expenditures on
prevention/surveillance. The first three components, calculated as costs
per case by a micro-costing approach (PAATI; program, actions,
activities, tasks, inputs), were scaled up to overall cost using
epidemiology data from official databases. PAATI was used to calculate
cost of vector control and prevention, education, and epidemiological
surveillance, based on an expert consensus and normative construction of
an ideal scenario.
Disability-adjusted life years (DALYs) for Mexico in 2016 were
calculated to be 2283.46 (1.87 per 100,000 inhabitants). Overall
economic impact of dengue in Mexico for 2012 was US$144 million, of
which US$44 million corresponded to direct medical costs and US$5
million to the costs from the patient's perspective. The estimated cost
of prevention/surveillance was calculated with information provided by
federal government to be US$95 million. The overall economic impact of
DF and DHF showed an increase in 2013 to US$161 million and a decrease
to US$133, US$131 and US$130 million in 2014, 2015 and 2016,
respectively.
Conclusions/Significance
The medical and economic impact of dengue were in agreement with other
international studies, and highlight the need to include governmental
expenditure for prevention/surveillance in overall cost analyses given
the high economic impact of these, increasing the necessity to evaluate
its effectiveness.
Filiaciones:
Zubieta-Zavala A.:
Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico
López-Cervantes M.:
Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico
Salinas-Escudero G.:
Center for Economic Studies and Social Health, Children's Hospital of Mexico Federico Gómez, Ministry of Health, Mexico City, Mexico
Ramírez-Chávez A.:
Private practice, Mexico City, Mexico
Castañeda J.R.:
Departamento de Arbovirus, National Institute of Public Health, Cuernavaca, Mexico
Hernández-Gaytán S.I.:
Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico
López Yescas J.G.:
Medical Affairs, Sanofi Pasteur Latin America, Mexico City, Mexico
Durán-Arenas L.:
Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico
|